Cisplatin
Patrick Joseph Loehrer, Lawrence H. Einhorn · Annals of Internal Medicine · 1984
Cisplatin is a metal coordination compound that was approved for clinical use in treating testicular cancer 5 years ago. Although early trials showed marked gastrointestinal and renal toxicities, treatment-related morbidity has been significantly alleviated with modern antiemetic therapy and adequate pretreatment hydration. More recent clinical studies of cisplatin have shown a broad range of activity and provide a better understanding of the drug's pharmacology, mechanism of action, and toxicity. Variations in the dosage and mode of administration as well as development of cisplatin analogues are being currently studied.
Cited by 947 works. doi:10.7326/0003-4819-100-5-704
Authors
References
- Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules
- High-Dose Cisplatin in Hypertonic Saline
- Intraperitoneal Cisplatin with Systemic Thiosulfate Protection
- Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer
- Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin
- Fertility after chemotherapy for testicular cancer.
- The Control of Chemotherapy-Induced Emesis